Inspired by mechanistic studies in AD and PD patients by which SGLT2 inhibitors have a positive impact in cognitive decline and neuronal apoptosis, we hypothesize that the possible mechanisms underlying the beneficial effect of SGLT2 inhibitors on the HPO axis may be attributed to reduction in brain oxidative stress and amelioration of hypothalamic neuroinflammation. The gene discussed is SLC5A2; the disease is Parkinson disease.